C43.9

Malignant melanoma of skin, unspecified

Malignant melanoma is a highly aggressive form of skin cancer that originates in the melanocytes, the pigment-producing cells located in the basal layer of the epidermis. Code C43.9 refers to a melanoma of the skin where the specific anatomical location is not documented or specified in the clinical record. Melanoma is characterized by its significant potential for lymphatic and hematogenous metastasis, making it the most lethal form of skin cancer if not diagnosed in early stages. Pathophysiologically, it often involves mutations in the MAP kinase pathway, most notably the BRAF V600E mutation, which leads to uncontrolled cellular proliferation. Chronic and intense episodic UV radiation exposure is the primary environmental driver, causing direct DNA damage and immunosuppression. Prognosis is heavily dependent on the Breslow depth (thickness of the tumor) and the presence of ulceration at the time of biopsy.

Clinical Symptoms

  • Asymmetrical skin lesion or mole
  • Irregular or blurred borders of a pigmented lesion
  • Color variation within a single mole (shades of black, brown, tan, blue, or red)
  • Diameter greater than 6mm (approximately the size of a pencil eraser)
  • Evolution or change in size, shape, or color of a pre-existing mole
  • Itching, tenderness, or localized pain in a skin lesion
  • Spontaneous bleeding or oozing from a mole
  • Development of a new pigmented or unusual growth on the skin
  • Ulceration or failure of a skin lesion to heal
  • Satellite pigmentations around a primary lesion

Common Causes

  • Excessive exposure to ultraviolet (UV) radiation from sunlight
  • Frequent use of indoor tanning beds and sunlamps
  • History of blistering sunburns, particularly during childhood or adolescence
  • Genetic predisposition and family history of melanoma (CDKN2A or CDK4 mutations)
  • Presence of multiple atypical nevi (dysplastic nevus syndrome)
  • Fair skin phenotype (Fitzpatrick types I and II) with tendency to burn
  • Immunosuppression (e.g., organ transplant recipients, HIV/AIDS)
  • Specific somatic mutations, most commonly BRAF, NRAS, and KIT
  • High total body mole count (greater than 50-100)
  • Personal history of non-melanoma skin cancers or previous melanoma

Documentation & Coding Tips

Prioritize anatomical site specificity over unspecified codes to ensure maximum clinical precision and coding accuracy.

Example: Patient presents with a 1.2 cm pigmented lesion on the right upper quadrant of the back. Biopsy confirms malignant melanoma. Plan: Wide local excision. Billing Focus: Identification of the right back as the specific site (C43.52) rather than unspecified skin (C43.9). Risk Adjustment: Increases the specificity of the HCC (Hierarchical Condition Category) mapping for neoplastic disease.

Billing Focus: Laterality and precise anatomical location (e.g., right upper quadrant of back).

Incorporate Breslow depth and Clark level in the documentation as these are critical for staging and prognosis.

Example: Assessment: Malignant melanoma of the left lower leg, Breslow depth 1.5mm, Clark level IV, no ulceration noted. Patient has comorbid Type 2 Diabetes Mellitus with neuropathy. Billing Focus: Documentation of depth supports the medical necessity for specific surgical margins in excision codes (11600-11646). Risk Adjustment: Depth and level indicate severity of the malignancy, influencing long-term care complexity.

Billing Focus: Depth and clinical staging details.

Document the presence or absence of ulceration and lymph node involvement clearly within the assessment and plan.

Example: Diagnosis: Malignant melanoma of the scalp, ulcerated, with palpable left cervical lymphadenopathy. Stage III clinical suspicion. Billing Focus: Scalp specificity (C43.4). Risk Adjustment: Ulceration status is a major prognostic factor and increases the clinical complexity documented in the risk profile.

Billing Focus: Ulceration status and regional node involvement.

Differentiate between primary melanoma and metastatic sites to avoid billing errors and ensure accurate disease tracking.

Example: Patient with known malignant melanoma of the skin, unspecified site, now presenting with metastatic nodules in the lung and liver. Documentation clearly distinguishes primary vs. secondary sites. Billing Focus: Primary site C43.9 with secondary sites C78.01 and C78.7. Risk Adjustment: Metastatic status significantly increases the risk-adjusted score and expected costs.

Billing Focus: Primary versus secondary (metastatic) site distinction.

Always document the presence of associated comorbidities such as immunosuppression which can complicate treatment.

Example: Patient with malignant melanoma of the trunk and underlying history of renal transplant on chronic immunosuppressants. Billing Focus: Interaction between malignancy and immunosuppression status (Z94.0). Risk Adjustment: Immunocompromised status adds to the complexity of managing the malignancy, reflecting a higher risk score.

Billing Focus: Secondary conditions impacting treatment planning.

Relevant CPT Codes

Related Diagnoses

Hierarchy